(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
The German series proving subtitles can be sexy — and wildly addictive- Supportive Tips On Home loans For First-Time Home Purchasers
- 5 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- The Extraordinary Excursion of Dental Embed Innovation
- Most loved Web-based feature: Which Stage Do You Like
- 'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
- Astounding Treehouses All over the Planet
